239 related articles for article (PubMed ID: 29258093)
1. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Naik GS; Ming WK; Magodoro IM; Akinwunmi B; Dar S; Poulsen HE; Kristensen LE; Ellervik C
Dermatology; 2017; 233(5):366-377. PubMed ID: 29258093
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
Mourad A; Gniadecki R
J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
[TBL] [Abstract][Full Text] [Related]
5. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
6. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
[TBL] [Abstract][Full Text] [Related]
8. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.
Ravindran V; Scott DL; Choy EH
Ann Rheum Dis; 2008 Jun; 67(6):855-9. PubMed ID: 17827183
[TBL] [Abstract][Full Text] [Related]
10. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression.
Druyts E; Palmer JB; Balijepalli C; Chan K; Fazeli MS; Herrera V; Jansen JP; Park JJH; Kanters S; Reimold A
Clin Exp Rheumatol; 2017; 35(4):681-688. PubMed ID: 28094756
[TBL] [Abstract][Full Text] [Related]
11. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
Goulabchand R; Mouterde G; Barnetche T; Lukas C; Morel J; Combe B
Ann Rheum Dis; 2014 Feb; 73(2):414-9. PubMed ID: 23355079
[TBL] [Abstract][Full Text] [Related]
12. The role of IL-17 in the treatment of psoriatic arthritis.
Lubrano E; Perrotta FM
Expert Rev Clin Immunol; 2017 Aug; 13(8):815-821. PubMed ID: 28485176
[TBL] [Abstract][Full Text] [Related]
13. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.
Wu D; Yue J; Tam LS
Rheumatology (Oxford); 2018 Mar; 57(3):563-571. PubMed ID: 29244162
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
17. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
[TBL] [Abstract][Full Text] [Related]
18. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
Reygaerts T; Mitrovic S; Fautrel B; Gossec L
Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders.
Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
Clin Rheumatol; 2019 Oct; 38(10):2747-2756. PubMed ID: 31165341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
